Rpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]CLINICAL RESEARCHMikirova N.A. et al.: Effect of high dose vitamin C on Epstein-Barr viral infection ?Med Sci Monit, 2014; 20: 725-Table 1. EBV EA IgG values prior to and immediately after IVC therapy in 35 subjects. Percentage of decrease in early antibody IgG levels () is offered. EBVEarlyAg,IgG Just before 195 195 257 58 38 130 130 123 67 26 37 108 130 48 22 44 44 138 83 80 91 47 47 57 29 39 48 108 42 29 64 60 43 101 39 Immediately after 151 50 211 30 30 25 7 36 30 21 67 80 46 38 15 8 25 98 68 64 three 5 25 64 six 19 38 80 19 six 17 45 50 86 28 of transform D ( ) 22.56 74.36 17.90 48.28 21.05 80.77 94.62 70.73 55.22 19.23 -81.08 25.93 64.62 20.83 31.82 81.82 43.18 28.99 18.07 20.00 96.70 89.36 46.81 -12.28 79.31 51.28 20.83 25.93 54.76 79.31 73.44 25.00 -16.28 14.85 28.21 Therapies(IVC)numbersanddoses 7.5 g 15 g two 7 six 13 1 13 ten 8 5 five 8 8 eight two eight 1 1 1 1 2 1 7 7 1 ten 1 2 eight 20 ten 7 1 1 3 1 six 4 two 7 6 6 ten six two 17 11 11 8 25 g 9 16 30 g 50 g Total IVCs 11 23 6 13 1 13 ten 8 five five eight 8 8 2 eight 7 7 11 7 four 18 18 18 9 ten 1 2 8 20 10 7 1 5 12Subjects 1 2 three four five 6 7 8 9 ten 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34Days 90 200 138 50 75 50 200 119 178 60 132 one hundred 118 125 one hundred 108 43 118 91 134 177 243 100 87 67 209 125 50 110 60 107 55 102 70This operate is licensed beneath a Inventive Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseIndexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]Mikirova N.A. et al.: Impact of higher dose vitamin C on Epstein-Barr viral infection ?Med Sci Monit, 2014; 20: 725-CLINICAL RESEARCH120 100 80 60 40 20More than 5 IVCs No treatmentA60 50 40 30 20 10 0 0.Reduce in EBV IgGEBV-VCA -IgM100 150 Time (days)0.1.1.five 2.0 Vitamin C (mg/dl)two.three.Figure two. Percent reduce in EBV EA IgG levels over time for individuals receiving no IVC, or five IVC. Lines represent linear least squares fits to data.B600100 80 60 40 20 0 -20 Early IgG (ev)400 300 200 100 0 0.Decrease in EBV IgG0.1.1.5 two.0 Vitamin C (mg/dl)two.three.ten 15 Variety of IVC treatmentsFigure three.3-Hydroxy-4-methylbenzonitrile uses Percentage of reduce in EBV EA IgG levels more than time for individuals receiving IVC as a function of number of IVC therapies.Figure four. Antibody levels are plotted against plasma ascorbate concentrations for EBV VCA IgM (A) and EBV Early Antigen IgG (B).Price of Palladium(II) chloride Curve fits are exponential: y=42 exp (?.PMID:23376608 18x) (r=0.62) for any and y=114 exp(?.37x) (r=0.21) for B. Estimated p-values are p0.001 for any and p=0.08 for B.for subjects treated far more than 5 instances. When compared with untreated controls, the rate of decrease within the EBV antibodies for treated subjects are considerably distinct (p0.002) from these with the untreated subjects. The impact of variety of remedies is confirmed in Figure three, which shows how the percent improvement (lower in EBV EA IgG) enhanced because the quantity of treatment options increased. The transform in the percentage of improvement with variety of treatment options (slope of the line in Figure 3) is 2.7?.7 per therapy (p0.001).We also located evidence that EBV antibody expression correlates with plasma ascorbic acid concentrations. Figure 4 shows the inverse relationships among plasma ascorbic acid levels (pre-treatment) and EBV EA IgG and VCA IgM. The trend is for subjects with higher plasma ascorbic acid levels to possess lower EBV antigen loads; this can be especially correct for VCA IgM. Moreover, we found that the.